Holen Sie sich die Stockscreener-App
2.40
3.81%
-0.095
Handel nachbörslich:
2.41
0.01
+0.42%
Schlusskurs vom Vortag:
$2.495
Offen:
$2.49
24-Stunden-Volumen:
1.36M
Relative Volume:
0.68
Marktkapitalisierung:
$468.71M
Einnahmen:
$7.12M
Nettoeinkommen (Verlust:
$-24.17M
KGV:
-9.8603
EPS:
-0.2434
Netto-Cashflow:
$-41.95M
1W Leistung:
-10.78%
1M Leistung:
-17.53%
6M Leistung:
+0.00%
1J Leistung:
+70.21%
1-Tages-Spanne:
$2.40
$2.51
1-Wochen-Bereich:
$2.40
$2.845
52-Wochen-Spanne:
$1.18
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.40 | 468.71M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Roth Capital | Buy |
| 2025-11-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Global BMI Index - marketscreener.com
Ovid Therapeutics Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Modest Stock GainOperating Margin Analysis - dars.gov.et
OVID: Advancing novel epilepsy and CNS therapies with strong clinical progress and major market potential - TradingView
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo! Finance Canada
H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com
OVID Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus By Investing.com - Investing.com Canada
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus - Investing.com
Ovid Therapeutics Inc (NASDAQ: OVID) Share Price, OVID Stock News, OVID Share Price & Updates - Kalkine
Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us
September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - RTTNews
Ovid management has two September talks scheduled - Stock Titan
Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
OVID Financials: Income Statement, Balance Sheet & Cash Flow | Ovid Therapeutics Inc - Stock Titan
Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan
Ovid (OVID) Shares: Posts a 2.19% Gain to $2.80; Range Check: the Supplied Trading Band Runs From $2.66 to $2.94 in the Latest ReadingDividend ETF - vinanet.vn
Ovid (OVID) Momentum: Finishes 2.19% Higher at $2.80 at the Close; Range View: Traders Can Monitor the $2.66-$2.94 Range in the Current UpdateDeath Cross - vinanet.vn
Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus
Ovid Therapeutics Inc. (OVID) Stock Price, News, Quote & History - Yahoo Finance
Ovid Therapeutics Inc. (OVID) Latest Stock News & Headlines - Yahoo Finance
Ovid (OVID) Quarterly Figures: EPS Prints Above Forecast in the Latest Reading; Investor Response: The Share Price Adds 1.94% in Latest TradingProfit Inflection Point - vinanet.vn
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
OVID Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 1.07%Earnings Acceleration Picks - vinanet.vn
Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan
Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Ovid Therapeutics Inc (OVID) News, Articles, Events & Latest Updates - Stocktwits
Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan
Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OVID: Advanced pipeline, strong cash runway, and soticlestat monetization drive future growth - TradingView
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OVID: Advanced pipeline, strong cash reserves, and expanded leadership drive long-term growth - TradingView
Ovid Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Ovid Therapeutics Inc. Q2 2026: Revenue $0.7M, EPS $(0.08) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
OVID Q1 2026 Earnings: Slight EPS Beat Signals Cost Discipline Amid Pre-Revenue StageEPS Estimate Trend - dars.gov.et
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):